Bayer wins EU approval for Eylea syringe
The syringe provides a new streamlined method to administer Eylea
Read More
Tag: aflibercept
Regeneron’s Eylea wins FDA approval
The drug is the only VEGF inhibitor approved with two dosing options for diabetic retinopathy.
Read More
NICE backs Bayer’s Eylea, Novartis’ Lucentis for sight condition
Cost regulators for NHS-funded therapies in England and Wales have issued updated guidelines for the treatment of wet AMD, which continue to back use of both Bayer’s Eylea and Novartis’ Lucentis, but the GMC says doctors should not fear prescribing Roche’s Avastin off-label if they believe it is clinically appropriate and in the patient’s best interest.
Read More
NICE nod for new Eylea indication
The National Institute for Health and Care Excellence (NICE) has issued a final positive recommendation for Bayer’s Eylea as a treatment for adults for the treatment of visual impairment due to myopic chorodial neovascularisation.
Read More
Novartis’ eye drug on par with Eylea but with fewer injections
Novartis’ eye drug brolucizumab has been proven in trials to be non-inferior to Regeneron/Bayer’s Elyea in treating vision loss in patients with neovascular age-related macular degeneration (nAMD), but with fewer injections than its rival.
Read More
NICE backs Bayer’s Eylea to treat sight condition
Cost regulators have now published final guidance endorsing routine NHS use of Bayer’s Eylea for all patients with visual impairment due to branch retinal vein occlusion (BRVO), having initially recommended its use only in the second-line setting.
Read More
NICE widens scope of Bayer’s Eylea
Cost regulators are now backing NHS use of Bayer’s Eylea for all patients with visual impairment due to branch retinal vein occlusion (BRVO), having initially recommended its use only in the second-line setting.
Read More
NICE’s Eylea guideline ‘out of touch with clinical practice’
Bayer says it is disappointed that the National Institute for Health and Care Excellence is supporting NHS use of anti-VEGF therapy Eylea to treat a common cause of visual impairment only in the second-line setting.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
